A PYMNTS Company

AstraZeneca Buying CinCor For Up To $1.8 Billion

By  |  January 9, 2023

AstraZeneca has agreed to acquire to CinCor Pharma  for $26.00 per share in cash plus a contingent value right of $10.00 per share in cash payable upon a specified regulatory submission of a baxdrostat product.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Related: South Korean Regulator Fines AstraZeneca and Local Firm for Collusion

    Marc de Garidel, Chief Executive Officer at CinCor, said: “We are excited about the proposed acquisition of CinCor Pharma by AstraZeneca as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patie.